Skip to main content
Company profile
BioNTech SE logo

BioNTech SE

Pipeline21 assets

  • PumitamigPD-L1/VEGF-A / immunomodulator / Oncology
    Multiple solid tumors; NSCLC; SCLC; HCC; CRC; ES-SCLC; EGFRm NSCLC; glioblastoma; MPM; NEN; TNBC; PDACclinical
  • BNT325/DB-1305BNT325/DB-1305 / targeted therapy / Oncology
    Multiple solid tumorsclinical
  • BNT324/DB-1311BNT324/DB-1311 / targeted therapy / Oncology
    Multiple solid tumorsclinical
  • BNT321BNT321 / targeted therapy / Oncology
    Multiple solid tumors; HCC combinationclinical
  • Autogene cevumeranmRNA cancer immunotherapy / Oncology
    Adjuvant CRC; adjuvant PDACclinical
  • BNT116BNT116 / mRNA cancer immunotherapy / Oncology
    Advanced NSCLC; 1L advanced NSCLCclinical
  • BNT113BNT113 / HPV16 / mRNA cancer immunotherapy / Oncology
    1L HPV16+ HNSCCclinical
  • GotistobartCTLA-4 / immunomodulator / Oncology
    Metastatic NSCLC; metastatic CRPC; PROC; multiple solid tumorsclinical
  • BNT211BNT211 / cell therapy / Oncology
    Multiple solid tumorsclinical
  • BNT314/GEN1059BNT314/GEN1059 / immunomodulator / Oncology
    Multiple solid tumors; metastatic CRC combinationclinical
  • BNT329BNT329 / immunomodulator / Oncology
    Multiple solid tumorsclinical
  • BNT326/YL202BNT326/YL202 / targeted therapy / Oncology
    Multiple solid tumors; NSCLC combination; advanced/metastatic breast cancerclinical
  • BNT317BNT317 / immunomodulator / Oncology
    Multiple solid tumorsclinical
  • Trastuzumab pamirtecanHER2 / targeted therapy / Oncology
    Metastatic breast cancer; advanced/metastatic breast cancer combination; 2L endometrial cancer; multiple solid tumorsclinical
  • BNT162 + BNT161BNT162 + BNT161 / mRNA vaccine combination / Infectious diseases
    COVID-19-influenza combinationclinical
  • BNT163BNT163 / HSV / mRNA vaccine / Infectious diseases
    HSVclinical
  • BNT166BNT166 / Mpox / mRNA vaccine / Infectious diseases
    Mpoxclinical
  • BNT162BNT162 / COMIRNATY / SARS-CoV-2 / mRNA vaccine / Infectious diseases
    COVID-19Commercialmarketed
  • BNT351BNT351 / HIV / antibody mRNA / Infectious diseases
    HIVclinical
  • BNT164BNT164 / Tuberculosis / mRNA vaccine / Infectious diseases
    Tuberculosisclinical
  • BNT165BNT165 / Malaria / mRNA vaccine / Infectious diseases
    Malariaclinical

Latest news15 items

All news

BioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination at WCLC 2026

Pumitamig plus B7H3-targeting elfetabart drozuntecan delivers the first data in lung cancer for any PD-(L)1xVEGF bispecific immunomodulator combined with an antibody-drug conjugate, underscoring BioNTech’s leadership in novel-novel combination treatment strategies Updated overall survival data for

Presentation / Abstract • Phase 1/2WCLC oral presentation Tue, Sep 15, 2026, 12:30 PM KST

BioNTech Announces Second Quarter 2026 Financial Results and Corporate Update

Guido Oelkers, Ph.D., appointed to BioNTech Management Board as Chief Executive Officer, taking office by February 1, 2027, at the latest Advanced diversified pipeline now with 14 ongoing pivotal clinical trials and more than ten novel-novel combinations across major tumor types Multiple milestones

Global Data for BioNTech and Bristol Myers Squibb’s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial

First investigational PD-(L)1xVEGF bispecific immunomodulator to present global data showing encouraging efficacy in combination with chemotherapy in first-line non-small cell lung cancer across PD-L1 expression levels and subtypes, highlighting its potential to set a new standard of care Pumitamig

Interim Data • Phase 2ASCO oral presentation Sat, May 30, 2026

BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting

Pumitamig data from the ongoing Phase 2/3 ROSETTA Lung-02 trial in first-line non-small cell lung cancer mark the third global data set to consistently show encouraging anti-tumor activity for pumitamig in combination with chemotherapy Gotistobart Phase 2 overall survival data in patients with

Presentation / Abstract • Phase 2/3ASCO oral presentation Sat, May 30, 2026, 1:15 PM CDT

BioNTech Announces New ADS Repurchase Program

MAINZ, Germany, May 7, 2026 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced that it has authorized a new share repurchase program (the “Program”), under which the Company may repurchase American Depositary Shares (“ADSs”), each representing one ordinary

BioNTech Announces First Quarter 2026 Financial Results and Corporate Update

Five additional pivotal trials for pumitamig initiated during 2026 in collaboration with Bristol Myers Squibb Oncology pipeline strength and combination strategy highlighted through multiple clinical data updates, including pumitamig, gotistobart and antibody-drug conjugate programs Catalyst-rich

BioNTech and DualityBio’s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer

Trastuzumab pamirtecan, an investigational HER2-targeted antibody-drug conjugate, met the primary efficacy endpoint in a Phase 2 cohort of heavily pre-treated patients with HER2-expressing, recurrent endometrial cancer, an area of high unmet medical need Data demonstrated clinically meaningful

Trial Results • Phase 2
BioNTech SE • Endpoint Arena